Advanced technology accelerates pharmaceutical research and development
February 03, 2016 08:00 AM Eastern Standard Time
SILVER SPRING, Md.–(BUSINESS WIRE)–Aurotech Inc. announces the launch of the Drug Lifecycle Tracking Application (DLTA). Through DLTA, Aurotech helps companies simplify work and process management across the entire drug development cycle.
Pharmaceutical and contract research organizations (CROs) are under constant pressure to develop new medicines quickly and efficiently, while still following the stringent protocols enforced by the Food and Drug Administration (FDA) before and during clinical trials. Complexity and fragmentation in these billion-dollar industries can lead to inefficiencies, delays or extra expenses when it comes to drug development, but DLTA aims to significantly improve the process.
“We believe we can simplify drug development through better workflow solutions, empowering pharmaceutical and research organizations to focus on what’s really important: creating new drugs that lead to a better quality of life,” said Matt Mitchell, director of work management solutions at Aurotech.
DLTA provides a new visibility into the way companies test and make new medicines, and helps those companies meet the regulatory demands of the FDA. For a CRO, DLTA can be implemented to improve clinical trial workflows across large teams or projects. For a pharmaceutical organization, the solution can function as an end-to-end work management platform, where only disparate systems have existed before.
“We help companies break down the complex steps necessary in pre-clinical studies and clinical trials so they can more easily manage and document project and regulatory milestones,” said Mitchell. “The industry has never had an advanced tool to track the entire drug development lifecycle – from research initiation all the way to FDA submission.”
DLTA is built on a leading project-management platform overlaid with intimate knowledge of drug development and FDA requirements. The result is custom-mapped work management for the entire drug development lifecycle. Users have the ability to track, manage and monitor projects from centralized and easy-to-use dashboards, and in-system collaboration improves the effectiveness of handoffs between teams. When it comes to IND or NDA application submission, DLTA ensures that every step is compliant and complete.
Having this full visibility in drug development projects is “mission critical,” said Mitchell. “FDA re-submissions can cost millions and take months to fix. Imagine if the application was for the next life-saving treatment. With DLTA, the cost and time savings will be significant, and it will help bring new medicine to patients more quickly.”
More about DLTA:
DLTA offers pharmaceutical organizations and CROs a comprehensive, cloud-based solution that is easy to implement and use. DLTA eliminates unnecessary distractions and fosters a highly efficient working environment, which affords all players to apply more focus on each of their respective tasks.
For more information, please visit http://www.druglifecycle.com
About Aurotech Inc.:
Aurotech Inc. is a leading-edge management and IT consulting firm founded in 1999. Aurotech offers clients a unique combination of public health subject-matter experts and IT professionals. We provide business re-engineering services to the federal government, including the FDA. Aurotech is now bringing its expertise to the pharmaceutical industry to create innovative, information-management solutions to meet the nation’s emerging health requirements.
For more information, please visit http://www.aurotechcorp.com